F.H. Investments, Inc. ("Asteria Health"), a wholly-owned subsidiary of biote Corporation, has initiated a voluntary recall of specific lots of hormone pellets shipped between May 20, 2025, and January 19, 2026. The recall was prompted by the potential presence of metal particulate matter. The company expects to record a one-time charge of approximately $1.3 million related to the write-off of impacted pellet inventory in the fourth quarter, with additional recall-related costs estimated at about $1.0 million in 2026. The recall is being conducted with the knowledge of the U.S. Food and Drug Administration and affected practitioners have been notified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. biote Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-022818), on January 26, 2026, and is solely responsible for the information contained therein.